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ABSTRACT 
Magnesium deficiency is described as the most under diagnosed 
electrolyte abnormality in current medical practice. Dietary magnesium 
deficiency is more prevalent than generally expected and remains to be one of 
the most common nutritional problems in the industrialized as well as the 
developing world. The chronic low magnesium diets are atherogenic and 
thrombogenic with association of a number of common chronic diseases like 
hypertension, diabetes and intensify the pre-existing cardiovascular diseases 
like stroke. 
Aims and objectives: 
To study the prevalence of serum magnesium deficiency in patients with 
acute ischemic cerebrovascular accidents. To assess the correlation between low 
magnesium levels and its association with diabetes mellitus, systemic 
hypertension, dyslipidemia and coronary heart disease. 
Materials and methods: 
 60 patients who met the inclusion and exclusion criteria were selected. 30 
patients who were admitted with a diagnosis of acute ischemic stroke were 
taken as cases. 30 patients were recruited from the outpatient department to 
participate in the study as controls. Serum magnesium levels were checked at 
the time of patients’ admission. 
Observation and results: 
In our study, it was observed that 70% of the cases and 30% of the 
controls were deficient in magnesium. The mean serum magnesium levels were 
1.39 and 1.76 in cases and controls respectively [P<0.05] which proved the 
association of ischemic stroke with the low magnesium levels. This study also 
showed a statistically significant relationship of association of systemic 
hypertension (p<0.00), dyslipidemia (p<0.00) with the serum magnesium 
deficiency. 
Conclusion 
 In conclusion, the present study showed a statistically significant 
correlation between serum magnesium deficiency with the ischemic stroke and 
its risk factors diabetes, systemic hypertension and dyslipidemia. 
CONTENTS 
 
1. AIM OF THE STUDY 
2. INTRODUCTION  
3. REVIEW OF LITERATURE 
4. METHODS AND STUDY DESIGN 
5. OBSERVATION AND RESULTS OF THE STUDY 
6. DISCUSSION 
7. LIMITATIONS OF THE STUDY 
8. IMPLICATIONS FOR THE FUTURE 
9. CONCLUSION 
 
 APPENDIX 
1. BIBLIOGRAPHY 
2. ABBREVIATIONS 
3. QUESTIONNAIRE 
4. MASTER CHART 
5. ETHICAL COMMITTEE APPROVAL CERTIFICATE 
 
 
 
AIM OF THE STUDY 
 
1. To study the prevalence of serum magnesium deficiency in patients 
with acute ischemic cerebrovascular accidents. 
2. To assess the correlation between low magnesium levels and its effect 
on serum cholesterol.  
3. To study the relationship between serum magnesium deficiency and 
diabetes mellitus, systemic hypertension and coronary heart disease.  
4. To assess the prognosis of acute ischemic stroke patients in 
accordance with the serum magnesium levels. 
 
 
 
 
 
 
 
 
INTRODUCTION 
Dietary magnesium deficiency is more prevalent than generally expected 
and remains to be one of the most common nutritional problems in the 
industrialized as well as the developing world. This is due to the result of 
current change in the dietary trends, agricultural practices and the food 
preparation techniques. World health organization and other health agencies say 
that more than 75-80% of the people do not consume the recommended daily 
intake of magnesium
(1)
. 
Magnesium depletion is described as the most under diagnosed 
electrolyte abnormality in current medical practice. Magnesium is gaining 
greater importance, as its deficiency is found to be a common problem and the 
prevalence of magnesium deficiency in hospital settings has been found to be 7 
– 11 %. Its deficiency also coexists with other electrolyte abnormalities in 40% 
of the patients 
(2)
. Due to the change in the dietary habits, an average human’s 
diet is deficient in magnesium. This is more common in the alcoholics, young 
people, and people who receive certain medications. In otherwise normal people 
the chronic low magnesium diets are atherogenic and thrombogenic and disrupts 
the arterial and cardiac integrity and so, it is associated with a number of 
common chronic diseases like hypertension, diabetes, coronary, heart disease, 
stroke, osteoporosis, etc.
 (3)
.  It can also intensify the pre-existing cardiovascular 
damage caused by the cardio-toxic drugs and other dietary factors like excess 
fat intake.  
  The National Institute of Health published in its website, “Magnesium is 
needed for the correct metabolic function of more than 350 enzymes in the 
human body. It helps in proper normal functioning of nerves and the muscles, 
maintains a strong immunity against infections, keeps the heart work in regular 
rhythm and supports the bone integrity. It regulates the blood sugar values, 
keeps the blood pressure under control, and also has a role in protein synthesis 
and energy metabolism. There’s a developing interest in the magnesium role in 
the prevention and treatment of diseases like diabetes, hypertension, cardiac and 
cerebral disorders.” It is thus magnesium deficiency is considered to be an 
epidemic deficiency. 
(4) 
           Magnesium is a natural antagonist of calcium and it helps in maintaining 
the tone and pressure in the blood vessels and the peripheral arterial blood flow. 
So, in its deficient state triggers vasoconstriction and enhances the injury to the 
vascular endothelial cells, thereby, promoting the progression in the process of 
atherogenesis. Virtually magnesium can affect every system of our body and is 
associated with every known disease.  
For several hundred years, magnesium has been used as a therapeutic 
agent. A large number of benefits have been obtained from magnesium therapy, 
from antacid and laxative therapy to cytoprotection of transplanted organs.  
           In patients with acute ischemic stroke, for the majority of them, there is 
presently no widely applicable treatment, despite recent encouraging results 
with rt-PA. The results from various trials and preclinical studies have shown 
that, a number of agents that offer neuroprotection are in the developing stages 
of clinical advancement and have at last begun to change the treatment of 
ischemic stroke in everyday clinical practice. 
           In the pathogenesis of acute ischemic stroke, there are many factors that 
have an impact on the cellular injury and the extent of the area affected after 
ischemic damage or traumatic brain injury and subsequently on the patients 
function and prognosis. One among the factors is the neuroprotectant 
magnesium.
 
Several studies have proved the hypothesis that in ischemic strokes, 
higher serum magnesium levels is accompanied by higher global function and 
better prognosis and administration of magnesium sulphate is associated with 
improvement in the neurological status and has effect on early recovery.
 
          The present study was undertaken to evaluate whether there is correlation 
between serum magnesium levels of the patient with acute ischemics stroke and 
also on the other cardiovascular risk factors like hypertension, diabetes and 
dyslipidemia. 
 
REVIEW OF LITERATURE 
STROKE: A “BRAIN ATTACK” - NEGLECTED  SILENT  EPIDEMIC  
 
DEFINITION 
 A stroke, or cerebrovascular accident, is defined by the abrupt onset of a 
neurologic deficit that is attributable to a focal vascular cause which lasts more 
than 24 hours. 
(5) 
 
STROKE STATISTICS: 
In the recent years, there is a shift in the diseases caused by poverty 
towards lifestyle-related chronic non communicable diseases in the developing 
countries due to the increase in the development of the economy and 
demography. In the developed as well as the developing countries, stroke 
remains to be the leading cause of serious long term neurological disability and 
also makes an important contribution to morbidity and mortality. In the world, 
stroke remains the third common most cause of death following coronary artery 
disease and cancer.   It is also the fourth leading cause of disease burden. 
(6)
 The 
prevalence of stroke is nearly three-fourths more than the sixth decade. There is 
no age limit for the occurrence of stroke. One fourth of the overall incidences of 
strokes occur in young people less than the age of 65 years. 
(7)
 After the age of 
55, the stroke risk is doubled for each decade. 
(8)
  
WORLDWIDE STATISTICS: 
           The incidence of stroke worldwide is 0.22 per 1000. Accordingly to the 
reports of the World Health Organization (WHO), every year worldwide, 
approximately around 15 million people are struck by stroke. Out of these 
strokes, 12.7 million are due to the higher systemic blood pressure. Of the 15 
million people, around one third die and another one third have a permanent 
disability.
(9)
 The number of people who are suffering from stroke is decreasing 
in the economically well developed countries, largely due to the fact that greater 
efforts are being taken to reduce hypertension and in reducing the smoking 
habit. However, due to ageing of the population, overall incidence of stroke 
remains to be high.
 
 
 STROKE: THE SCENARIO IN INDIA 
        It is a major health problem in India. When compared to the developed 
countries, where it has reached plateau or has decreased, the burden of stroke 
has been rising in India. In India, of all the strokes, ischemic stroke contributes 
to around 80% and intracranial atherosclerosis appears to be commoner in 
Indian people. 
 
           It is estimated that approximately 1.6 million cases of stroke will be 
reported annually by the year 2015, out of which at least one third of them will 
have disability. By 2050, WHO has estimated that, 80% of all the strokes in the 
world would occur in the low and middle income countries, mainly India and 
China 
(10)
. It was found in Indian studies that about 10-15% of all the strokes 
that occur is found in the people below 40 years.  
 
 PROGNOSIS  
           Stroke remains the most common cause of neurological disability in the 
world. Patients who had suffered from stroke have a worse prognosis than for 
any type of cancer. Approximately after one year of the onset of stroke, half of 
all patients are dead or on survival becomes functionally dependent at one year. 
The Indian Council of Medical Research (ICMR) estimated that stroke 
contributes for 41 per cent of deaths and 72 per cent of disability adjusted life 
years (DALYS) among the non communicable diseases (NCDs).
(11)
 Many other 
clinical problems like seizures, falls, fractures, depression and dementia 
secondary to stroke occur. So these patients are left with residual disabilities 
like physical dependence which leads to enormous socio-economic impact on 
individuals, families and health care institutions. 
 
RISK FACTORS OF STROKE: 
           Various prospective epidemiological studies and the Framingham Heart 
Study identified hypertension, diabetes mellitus, hyperlipidemia, and smoking 
as the major atherogenic risk factors for stroke. 
 
 
 
RECENT TRENDS IN THE MANGEMENT STRATEGY OF STROKE 
 
 In the recent time, there has been a dramatic improvement in the 
management of the ischemic stroke. Therapeutic management of acute ischemic 
stroke has been divided into the therapies that target the vasculature and those 
that target the nervous system. Current vascular strategies are limited to 
recanalization by clot removal (tPA thrombolysis, intraarterial fibrinolysis, 
mechanical removal), prevention of the clot propagation with aspirin and statins 
and by enhancement of the collaterals. These agents protect the brain are 
primarily through the hemodynamics rather than the metabolic mechanisms.
(12)
   
 
INTRAVENOUS THROMBOLYSIS 
The benefit of intravenous thrombolytic therapy in acute brain ischemia is 
strongly time dependent. Therapeutic yield is maximal in the first minutes after 
symptom onset and declines steadily during the first 3 hours. Patients who 
present to hospital within the first 60 minutes of onset (the “golden hour”) have 
the greatest opportunity to benefit from recanalization therapy.
(13)
 Target DTN 
(door to needle) ≤ 60 mins achieved in less than one fifth of golden hour-
arriving patients. In a typical acute ischemic stroke, every minute the brain loses 
1.9 million neurons, 14 billion synapses, 7.5 miles myelinated fibers. 
(14)
 Every 
10 minute delay in delivery of TPA, 1 fewer patient has improved. 
 
  Every patient who reaches the medical setups within 4.5 hours of having 
had the event, there exists  a possibility of thrombolysis. The time until the area 
becomes irreversibly damaged is the therapeutic window.
(15)
 The window period 
for intravenous thrombolysis has recently been widened from three hours to 4.5 
hours. 
(16)
 However, only a small proportion of stroke patients can avail of this 
therapy. So, the major target for stroke is in protecting the brain from ischemic 
damage. 
           Current neural strategies for the treatment of ischemic stroke include 
acute neuroprotection and the sub acute promotion of brain plasticity. Various 
neuroprotective agents like glycine antagonists, calcium antagonists, free radical 
scavengers, etc., which are likely to intervene one of the various steps in the 
mechanisms of ischemic cell injury have been tried in the past as a part of the 
strategy for treating ischemic strokes. 
(17)
 But they were found to be either 
ineffective or too toxic to be used in humans.    
           In acute ischemic cerebrovascular accident, there has been a considerable 
progressive development in the understanding of its physiology and 
pathogenesis. 
 
 ISCHEMIC CASCADE IN THE PATHOGENESIS OF STROKE 
After occlusion of the intracranial cerebral vessels, a series of time 
dependant neurochemical events takes place called the ischemic cascade which 
results in energy failure. 
 
ISCHEMIC CASCADE 
 
 The neuropathogenic processes (Fig 1) involved in this ischemic insult include,   
1. The glutamate, an excitatory amino acid (EAA) is the most excessive excitatory 
neurotransmitter in the brain stored in the presynaptic vesicles. When it is 
released, it binds to the post synaptic glutamate NMDA (N- methyl D-aspartate) 
receptor. 
(18)
 
2. Once the reduction of cerebral blood flow commences, there is abundant release 
of excitatory neurotransmitters, especially glutamate and causes excess 
activation of the NMDA receptor. 
3.  Activation of these receptors leads to the influx of the calcium and the sodium 
ions through the ligand and voltage gated channels. 
4. The intracellular enzyme systems which are dependent on calcium are activated 
and leads to the induction of 
i. free radical production(19) 
ii. membrane lipid breakdown proteolysis 
iii. initiation of an inflammatory response which stimulates 
apoptosis 
 
Fig 1: SCHEMATIC DIAGRAM OF SECONDARY CELLULAR RESPONSES IN 
RESPONSE TO DIRECT AND INDIRECT NEURONAL INJURY 
(28) 
   
  
5. All of this contribute to compromise of the metabolic functions, expansion of 
the infarct volume and the development of neurotoxicity over a timescale of 
days or even weeks 
6. The leucocyte and platelet activation cause direct micro vascular damage and 
worsen ischemia.
(20)
 
 
ISCHEMIC PENUMBRA 
 
Fig 2: COLLATERALS AFTER MIDDLE CEREBRAL ARTERY OCCLUSION
(29) 
 
             The ischemic penumbra can be broadly defined as that region of the 
ischemic zone that is potentially salvageable. 
(15)
 After the middle cerebral 
artery is occluded, (Fig 3) the blood flow of the core region decreases below 
around 10 ml/100 g/min, which leads to rapid necrosis of this region. 
Surrounding the core region is the region of ischemic penumbra, where the 
collaterals support a blood supply of 10–20 ml/100 g/min.(19) Majority of the 
ischemic cascade occurs within this ischemic penumbra and many of the 
important biochemical reactions of this cascade occur within the first two hours 
of the onset of focal ischemia. 
(21)
  
 
Fig 3: BLOOD FLOW IN THE ISCHEMIC CORE AND THE PENUMBRA 
(22) 
 
The infarct core is surrounded by the ischemic penumbra which is 
functionally impaired but potentially viable tissue and can persist for upto 48 
hours of the onset of the stroke. Unless an intervention occurs, either by 
promoting reperfusion with thrombolysis or by attenuating the ischemic cascade 
with neuroprotective agents, the penumbra is destined to necrosis due to the 
metabolic and neurochemical consequences of ischemia 
(23) 
The main aim of treatment in acute stroke is in improving the disparity 
between the demand and the energy supply of the brain thereby   minimizing the 
neuronal damage which can be done by restoring local blood flow, supplying 
alternative metabolic substrates, by reducing neuronal metabolism or by 
interfering with the complex mechanisms which can eventually lead to neuronal 
death after an ischemic insult thereby, protecting against the toxic effects of the 
ischemic cascade and improving the overall metabolic environment.
(20)
  
           There are only few specific treatments available for minimizing this 
acute injury of brain ischemia, which is a medical emergency. Current therapies 
are limited to clot removal (tPA thrombolysis, intraarterial fibrinolysis, 
mechanical removal), aspirin, and decompressive hemicraniectomy for ischemic 
stroke and moderate hypothermia (33°C) for cardiac arrest.  
 
THE NEED FOR NEUROPROTECTION: WINDOW OF 
OPPORTUNITY 
           In humans, following an ischemic damage, the neurological insult 
produced spreads from the central core of the infarct. The excitotoxic injury 
continues beyond 48 hours to produce the maximal size of the infarct, and the 
local cerebral perfusion and the autoregulation are disturbed for the first 72 
hours.
(24)
 In most of the cases, within three to four days, the collateral vessels 
develop and reperfuse the damaged areas and the regional blood flow 
abnormalities tend to resolve.
(25)
 The PET (Positron Emission Tomography) 
imaging, which can distinguish ischemia from an infarct, cannot identify the 
areas of ischemia which will recover or transform into an infarct. It was found 
that blood flow was reduced locally in 100% of patients within 9 hours of the 
insult and it was reduced to 30% within 4 days. Following stroke, this ischemic 
but viable tissue was found for upto 48 hours. Because the hemorrhagic 
complications are high when reperfusion is done at later stages, the time 
window for thrombolysis is relatively short. So there is a rationale for need of 
initiating neuroprotective measures to prevent the continuing cerebral ischemia 
and to salvage the viable ischemic tissue during the time the cerebral 
autoregulation is deranged and the collateral circulation is developing (ie,3 to 4 
days after the onset of stroke) when patient comes beyond the critical time 
allocated for thrombolysis.
(26)
  
 
NEUROPROTECTION: TIME IS BRAIN 
  The main treatment strategies for therapeutic intervention in ischemic 
stroke are aspirin and thrombolysis. The concept of neuroprotection emerged 
only recently and is considered as an alternative additional intervention because 
of its relative safety, evidence of efficacy in animal models and potential to 
administer in the pre-hospital setting.
(27)
 Thousands of experimental papers and 
more than 500 articles have been published on neuroprotection to emphasize its 
potential utility.  
 
BASIC CONCEPTS OF NEUROPROTECTION: 
           Neuroprotection in ischemic stroke refers to the therapeutic interventions 
applied in single or in combination which will counteract, block, or slow the 
sequence of the injurious biochemical and molecular events that take place in 
the cascade of the irreversible ischemic brain injury. 
(28)
 Rigorously conducted 
experimental studies in animal models of brain ischemia provide 
incontrovertible proof of evidence that high grade protection of brain is an 
achievable goal.   
           A number of possible approaches have been suggested, considering the 
pathophysiological processes of neuroprotection.   
Excitotoxicity can be attenuated 
(20)
 by 
1. Decreasing the release of the excitatory neurotransmitters (especially glutamate) 
(Fig 4) or increasing its reuptake or its breakdown  
2.  Reducing their toxicity by blocking or down-regulating post-synaptic NMDA 
receptors 
3.  The release of inhibitory amino acids or the neurotransmitters like gamma-
aminobutyric acid (GABA) can be stimulated.  
4. By blocking the voltage-sensitive channels, the calcium influx is reduced by 
promoting its extrusion or sequestration there reducing the toxicity of excess 
intracellular calcium. 
5.  Modifying the other ‘downstream’ intracellular processes, such as the various 
nitric oxide-dependent pathways.  
6. Other ways for neuronal salvage include the reduction of cerebral oedema, 
correcting acidosis and scavenging free radicals. 
 
 
Fig 4: MAJOR STEPS IN THE CASCADE OF CEREBRAL ISCHEMIA
 
CLASSIFICATION OF NEUROPROTECTIVE AGENTS
(18) 
1. Modulators of Excitatory Amino Acids 
2. Modulators of Calcium Influx 
3. Metabolic Activators 
4. Anti-edema Agents 
5. Inhibitors of Leukocyte Adhesion 
6. Free Radical Scavengers and Anti-Oxidants 
7. Promotors of Membrane Repair 
The most extensively studied and the promising neuroprotective agents are the 
hyperacute magnesium therapy, therapeutic hypothermia, high dose human 
albumin, calcium channel blockers, GABA agonists, glutamate antagonists, 
antioxidants, free radical scavengers, down-regulators of the nitric oxide signal 
transduction. 
(29)
 
Unlike the other majority neuroprotective agents, magnesium is used 
extensively for many clinical conditions like arrhythmias, myocardial infarction 
and pre-eclampsia/ eclampsia.
(30)
 So these major clinical experiences confirm its 
tolerability, efficacy and safety.  In recent times, many clinical trials conducted 
had proved the neuroprotection offered by magnesium and improvement in 
neurological outcome in patients with ischemic stroke. 
 
THE VITAL MAGNESIUM – THE “FORGOTTEN CATION” 
 Magnesium is found in each and every cell of the body. The main source 
of energy in cells, ATP (adenosine triphosphate) is bound to the magnesium. It 
is vital for a normal biological function. So without it, there is no energy, no 
movement and no life. 
(31)
  It is the powerful calcium channel blocker and so it 
relaxes every muscle including the heart which is the vital muscle of our human 
body. Unlike the other medications which block the calcium channel, 
magnesium is a natural and nontoxic element which can be used safely. 
   
The fourth most abundant mineral in our body is magnesium. Around 
99% of the total body magnesium (Fig 5) is present in the bone, muscle and the 
soft tissue. Magnesium ion is present inside the cells at a concentration of 5 – 
20mmol/L; present in the ionized form in around 1-5%, remaining is bound to 
the proteins, and adenosine tri phosphate (ATP). During states of acute 
deficiency, large amount of exchangeable pool for magnesium is from the 
bones. As age increases, the magnesium content of bone also decreases. Only 
1% of the total intracellular magnesium is present extracellularly.
(32)
  The 
primary extracellular concentration is present in the red blood cells (RBCs) and 
serum. 
 
Fig 5: MAGNESIUM DISTRIBUTION IN A NORMAL HUMAN ADULT 
(33) 
 
Similar to calcium, magnesium is present in three forms (Fig 6) 
free/ionized, bound to proteins and anions like phosphate, bicarbonate, citrate or 
sulphate. The biological activity of magnesium is greater with the ionized form.   
 Fig 6: DISTRIBUTION OF THE TOTAL SERUM MAGNESIUM 
(34) 
FOODS RICH IN MAGNESIUM (Fig 7) 
 
           Vegetables like pumpkin seeds, sesame seeds, sunflower seeds, spinach, 
legumes and green beans are very rich sources of the mineral. Refined grains 
are deficient in magnesium. 
 
                  Fig 7: FOODS CONTAINING HIGHER MAGNESIUM 
HARDNESS OF WATER AND MAGNESIUM 
(35) 
“Hard water” which naturally contains abundant minerals is richer in 
magnesium than the “soft water.” It is said that 12% of the total daily 
magnesium intake is derived from the drinking water. If the person consumes 
only hard water, as much as 18% of the daily required magnesium can be 
obtained. For persons whose intake of magnesium from the food is marginal, 
these amounts might well be critical.  
 
MAGNESIUM HOMEOSTASIS (Fig 8) 
   
 
Fig 8: MAGNESIUM BALANCE 
Magnesium homeostasis is achieved mainly through the bones, intestines 
and the kidneys. It is absorbed mainly in the small intestine by the passive 
transport. Only 25 – 75% of the total magnesium consumed is absorbed. The 
remaining is excreted in the faeces. The absorption of magnesium in the 
intestines depends not on the levels consumed, but on its status of the body. 
Lower the magnesium levels, higher the ion is absorbed.  Serum magnesium 
levels are principally regulated by the kidneys. Around 95% of the filtered 
magnesium is reabsorbed and only 3 -5% is excreted in the urine.  The thick 
ascending limb of the loop of Henle is the primary site for reabsorption. 
(36) 
 
MAGNESIUM – MEMBRANE STABILIZER 
           Magnesium provides critical cell membrane stability for the cellular and 
the sub- cellular (organelle) structures. When it binds to the phospholipids, it 
decreases the membranes permeability. In low level states, the stability of the 
membrane is deranged, resulting in increase in permeability and the damage of 
the whole structural cell. 
(37)
 
 
MAGNESIUM – NATURE’S PHYSIOLOGICAL CALCIUM CHANNEL 
BLOCKER (Fig 9)   
Many calcium channels are found to be magnesium dependant. Higher 
levels of magnesium inhibit the flux of calcium from the sarcoplasmic reticulum 
and through the intra and extra cellular channels. So during deficiency state, 
there is unopposed influx of calcium and its levels increase intracellularly.                       
 Fig 9: BLOCAKADE OF CALCIUM CHANNELS BY MAGNESIUM 
(38) 
                       
 
Fig 10: INTRACELLULAR CALCIUM LEVELS IN A NORMAL AND MAGNESIUM 
DEFICIENT CELL
 
           Magnesium acts as a competitive antagonist of calcium as Mg
2+
 is a 
bivalent ion resembling Ca
2+
. (Fig 12) Both calcium and magnesium have 
opposite effects on the vascular tone. So hypomagnesemia causes spasm of the 
blood vessels and increases resistance in the blood vessels.
(39)
  
 Fig 11:  CELLULAR MECHANISMS INVOLVED IN HYPOMAGNESEMIA
 
 
Fig 12:  DELETERIOUS EFFECTS OF HIGH INTRACELLULAR CALCIUM DUE TO LOW 
MAGNESIUM 
(38) 
           An average 60 kg adult contains around 2000 mEq in the body. The 
normal serum magnesium values range between 1.5 – 2.5 mEq/L. (1 mEq = 0.5 
mmol = 12 mg). 
(40) 
 
 
 DAILY REQUIREMENTS FOR MAGNESIUM (Fig 13) 
 
 
Fig 13: RECOMMENDED DAILY ALLOWANCES FOR MAGNESIUM 
(41) 
(Published by the National Institute of Health (NIH)) 
 
MAGNESIUM DEFICIENCY 
           In the current westernization lifestyle of a calorie restricted diet, 
magnesium intake in the food and the drinking water has considerably reduced. 
Magnesium is almost missing in the bottled water which every healthy 
conscious people habituate to take in order to avoid the risk of contaminants 
particularly heavy metals and chlorine. From the bottled water only 30% of the 
recommended average daily intake of magnesium is obtained. The remaining 
70% had to be taken through magnesium rich food sources. National health and 
nutritional examination survey conducted in the United States has found that 
considerable amount of adults have failed to get the recommended intake of 
magnesium. In every ethnic and racial group, it was found that magnesium 
intake was considerably lower in the older adults. The prevalence of magnesium 
deficiency is found in less than 2% of the general population, 10-20% of the 
hospitalized patients, 50- 60% of the intensive care unit patients and 30-80% of 
the alcoholics.  
 
 
 
Fig 14: AVERAGE DAILY INTAKE OF MAGNESIUM (Mg) IN THE UNITED STATES 
(42)
 
(Reproduced from “Magnesium in the Pathogenesis of the Disease” Seeling, MS ) 
 Fig 15: INTAKE OF MAGNESIUM IN THE UNITED STATES
(42) 
 
HYPOMAGNESEMIA 
Serum magnesium levels less than 1.5 mEq/L is defined as 
hypomagnesemia. 
(36) 
The factors that influence magnesium levels are 
1. Inadequate dietary intake 
2. Decrease in the absorption of magnesium in the gastrointestinal tract 
a. Diarrhoea, vomiting 
b. Gastro intestinal suction 
c.  In chronic malabsorptive problems like Crohn’s disease, regional 
enteritis, intestinal surgeries and gluten sensitive enteropathy. 
d. Steatorrhoea 
e. Acute pancreatitis 
3. Increase in the renal excretion 
a. Renal tubular defect 
b. Alcoholism 
c. Diuretics- thiazides and loop diuretics 
d. Antimicrobials – aminoglycosides, amphotericin B 
e. Chemotherapeutic drugs – cisplatin, cyclosporine, tacrolimus 
 
 
   In terms of symptoms development the rate of development is more 
important than the absolute value. Cardiovascular and the nervous systems are 
the most affected in magnesium deficiency. The other systems are less 
commonly affected. 
Cardiovascular manifestations 
(36) 
Prolonged QT/QU interval, increased digitalis toxicity, torsades de 
pointes, ventricular fibrillation. 
Neuromuscular manifestations:  
Tremors, paresthesias, seizures, weakness of muscles, fasciculations 
tetany, letharginess, confusion, disorientation, irritability, agitation and 
psychosis. 
Physical examination: 
 In patients with seum levels less than 1mEq/L develop muscular 
fibrillations, tremor, carpopedal spasms can progress to tetany, deep tendon 
reflexes. Cardiac arrhythmias and respiratory failure can occur in patients with 
severe hypomagnesemia.  
MEASUREMENT OF SERUM MAGNESIUM
(36) 
It can be assessed by measuring magnesium levels of 
1. Total serum magnesium 
2. Red blood cell 
3. Mononuclear cell 
4. 24-hour urinary excretion 
5. Fractional excretion (FE) of magnesium 
6. Intracellular content of skeletal muscle 
 
Intracellular content of magnesium can be estimated using nuclear 
magnetic resonance spectroscopy or using fluorescent dye. Two things should 
be considered in estimation of serum magnesium. Firstly, most of the methods 
available estimate only the total serum magnesium. But only the free 
magnesium ion is functionally active. 30% of the magnesium is bound to 
albumin. So in hypoalbuminemic states, it can lead to falsely low values. So 
albumin levels should be considered in interpretation of magnesium.  Secondly, 
the intracellular magnesium plays a major physiological role. Estimating in the 
serum assess the extracellular magnesium which constitutes only 2% of the total 
body levels. So a person can have normal serum magnesium level but depleted 
at the intra cellular level. Unfortunately, no quick, simple, and accurate test is 
available to measure intracellular magnesium. 
TREATMENT  
Treatment is needed for patients with symptomatic hypomagnesemia with 
seizures or arrhythmias. Magnesium sulphate should be given intravenously in 
the dose of 2-4 grams given as 10% solution in 20 to 30 ml of 5% dextrose in 
water over 5 to 15 minutes. For repeated seizures, magnesium can be given to a 
total of 10 grams for the next 6 hours. 
(43) 
THE EPIDEMIC OF MAGNESIUM DEFICIENCY  
Magnesium is one of the most important electrolyte that is essential to the 
basic nucleic acid chemistry of life and so essential to all the known living 
organisms. It is a cofactor that is required for catalizing more than 350 
enzymatic reactions in the body. So its deficiency can affect every aspect of our 
physiology. In numerous diseases, magnesium deficiency is found as either 
being a causative factor, or as expediting various disease processes. 
 
 
 
MAGNESIUM DEFICIENCY: STATE OF LOW GRADE 
INFLAMMATION 
 There are various nutritional factors that affect the inflammatory 
response. Researches called out one particular common nutrient; magnesium in 
its deficient state is associated with a low grade inflammation. Magnesium has a 
role in regulating inflammation and decreasing the damage induced by the 
oxygen derived free radicals while deficiency increases oxidative stress and 
inflammation in humans. Various evidences from the studies prove that 
magnesium intake was inversely associated with the plasma concentrations of 
C- reactive protein (CRP), Interleukin- 6 and tumor necrosis factor-α. (44) Its 
deficiency is associated with conditions linked with chronic inflammation like 
heart disease, hypertension and diabetes. 
 
ARTERIAL ENDOTHELIAL DAMAGE CAUSED BY “PURE” 
MAGNESIUM DEFICIENCY
 
 The vascular changes caused by magnesium deficiency were studied in 
the animal experiments. The studies showed that the inflammatory changes (Fig 
16) in the arterioles and the capillaries were extracellular edema with intimal 
thickening, thinning and disruption of the internal elastic membrane, and 
disorientation and hyperplasia of medial muscle cells.
(45)
 Some arteries also had 
densely aggregated pyknotic cells in their enlarged tunica media, with narrowed 
lumina. Inspite of the low serum calcium levels, medial and intimal calcification 
was demonstrated in magnesium deficiency.  
In magnesium deficiency, the endothelial cell is greatly injured by the free 
radical mediated oxidative stress and intracellular lipid peroxidation. 
 
 
Fig 16: CORONARY ARTERIAL AND CARDIAC LESIONS CAUSE PURE MAGNESIUM 
DEFICIENCY
 
(Reproduced from “Magnesium in the Pathogenesis of the Disease” Seeling, MS.) 
 Fig 17: EFFECT OF MAGNESIUM ON THE VASCULAR SMOOTH MUSCLE AND THE 
ENDOTHELIUM  
  
MAGNESIUM DEFICIENCY AND ATHEROSCLEROSIS                      
           Atherosclerosis is the most important risk factor for the cardiovascular 
diseases mainly stroke and myocardial infarction. Large amount of evidence 
supports that the main causative factor responsible for the atherosclerotic 
burden in cardiovascular disease is the inflammation and the endothelial 
dysfunction. Various epidemiological studies from animal models suggest that 
magnesium deficiency at the cellular level accelerates the inflammation and 
intensifies the lipid deposition in the blood vessel wall and there is an inverse 
correlation cardiovascular incidence and the dietary magnesium. In the follow 
up of the ARIC study, it was demonstrated that for every 0.1mm decline there 
was increase in the thickness of carotid intima- media thickness with the 
development of carotid plaques.
(46)
                
 
Fig 18:  SCHEMATIC DIAGRAM OF THE ATHEROGENESIS 
(65) 
In magnesium deficiency, 
1. In the endothelium, (Fig 19) upregulation of the adhesion molecules like 
VCAM (vascular cell adhesion molecule), MCP-1(monocyte chemoattractant 
protein -1) and release of cytokines like platelet derived growth factor (PDGF), 
NFkβ (nuclear factor kappa- light chain- enhancer of activated B cells, 
interferons (IFs), interleukins (IL-1) etc are enhanced. 
(47)
 
                           
Fig 19:  EFFECT OF LOW MAGNESIUM ON THE ENDOTHELIAL FUNCTION 
(48) 
 
2. This leads to adhesion and migration (chemotaxis) of monocytes into the 
arterial wall and transformed into macrophages in the intimal layer. 
3. It enhances the permeability of the LDL cholesterol and promotes the oxidation 
of LDL in the carotid intima. (Fig 20)                                   
 
 
Fig 20:  LOOP BETWEEN LOW MAGNESIUM, ENDOTHELIAL DYSFUNCTION AND 
LDL OXIDATION 
 
   
4. In the carotid intima, there is increase in the uptake of oxidized LDL by the 
macrophages and the formation of foam cells thereby accelerating the 
inflammation and the atherogenic plaque formation which is the initiating event 
for all the cardiovascular diseases.   
 
 
 
Fig 21: PROATHEROSCLEROTIC EFFECTS OF OXIDIZED LDL
(48) 
 
So magnesium which is a natural and a safe element can be used as an 
adjuvant therapy for the prevention of atherosclerosis.  
 
MAGNESIUM - ANTITHROMBOTIC WITH CARDIOPROTECTIVE 
EFFECT 
(49) 
The protective mechanisms of magnesium are  
1. Reduction of the proinflammatory process 
2. Stabilization of the membrane of platelets as magnesium is needed to maintain 
the shape of the platelets. 
3. Inhibition of thrombogenesis through inhibition of ADP - platelet aggregation 
and adhesion.   
4. The release of the platelets is dependent on the calcium and so magnesium 
physiologically inhibits its release. 
5.  The platelet dependant thrombosis was inversely correlated with the serum 
magnesium levels and its supplementation positively reduced the size and the 
number of platelet clumps and increased the number of discrete platelets.   
6. Increase in the fibrinolytic activity. 
7. By lowering the intracellular calcium concentrations, it decreases the tonicity of 
the blood vessels and also inhibits the vascular calcification. 
8. Against oxidative stress, it helps to increase the protective enzymes.  
9. Increases the nitric oxide (NO) release and enhances the endothelial dependant 
vasodilatation and inhibits the aggregation of platelets.  
 
 
Fig 22: EFFECT OF INTRAVENOUS (i.v.) MAGNESIUM (Mg) ON THE PLATELET 
AGGREGATION 
(50) 
                           (Adapted from Adams and Mitchell,  ThrombHaemost). 
 
LOW MAGNESIUM AND DYSLIPIDEMIA 
Magnesium has an important role in control of the lipid metabolism. 
Dyslipidemia is found to be strongly associated with magnesium deficiency. 
The antiatherogenic effects of Mg2+ are due to the lipoprotein lipase, HMG 
CoA reductase, and lecithin acyltransferase enzyme modification of the lipid 
metabolism and turnover. It also modulates HMG-CoA reductase which is the 
main enzyme catalizing the rate limiting step in the cholesterol metabolism. So 
magnesium acts as a “physiological statin”. (51) Clinicians from the British 
Commonwealth have reported that treatment with magnesium has resulted in 
the reduction of β- lipoproteins and increments in lecithin/cholesterol ratio and 
α- lipoproteins. Its deficient state is associated with decrease in HDL-C fraction, 
inhibition of the enzyme lipoprotein lipase and causes elevation in the levels of 
TGL associated lipoproteins and plasma apolipoprotein B. 
(52) 
 
MAGNESIUM AND BLOOD PRESSURE 
 A clinical trial, DASH study (Dietary Approaches to Stop Hypertension) 
suggested that high intake of foods rich in magnesium, calcium and potassium 
and low in sodium like fruits and vegetables had significantly lowered the high 
blood pressure. 
(53)
 In an observational study, the ARIC (Atherosclerosis Risk in 
Communities) study was conducted in 8000 men and women who were initially 
free of hypertension was followed up for six years. In this study, during follow 
up, the patients who consumed diet more in magnesium, potassium and dietary 
fibres were found to be at a lower risk of developing hypertension. 
(54)
 Joint 
National Committee stated that the diets that provide higher magnesium are 
positive lifestyle modifications for people with hypertension and there is a dose 
dependant improvement in blood pressure with magnesium supplementation. 
 
MAGNESIUM DEFICIENCY IN TYPE 2DIABETES: 
           Magnesium has an important role in carbohydrate metabolism. 
Magnesium is required in the glucose metabolism for three critical enzymatic 
reactions namely pyruvate carboxylase, phosphoenol pyruvate carboxykinase, 
fructose 1,6 biphosphatase.  It also plays key enzymatic roles in various 
hormones like insulin, glucagon, adrenaline and cortisol which have a 
regulatory effect on gluconeogenesis. Hypomagnesemia may worsen the insulin 
resistance. 
(31) 
           Diabetes and metabolic syndrome are strongly linked to magnesium 
deficiency. Type2 diabetics are always in an overactive dominant sympathetic 
state, which leads to elevated blood glucose and blood pressure. Magnesium 
inhibits this excess activation of the sympathetic nervous system thereby 
preventing the development of hypertension and hyperglycemia. Researchers 
have found that people who had taken more magnesium from food and various 
vitamin supplements were half as less likely to develop type2 diabetes than 
people who took the least amount of magnesium.  
 
Fig 22: Role of magnesium and calcium in the pathophysiology of hypertension, 
diabetes mellitus, and atherosclerosis. 
(55) 
MAGNESIUM AND CORONARY ARTERY DISEASE 
           Anderson et al. (1969) gave an hypothesis that there is an environmental 
factor magnesium, alters the excitability of the myocardium, which in deficient 
levels causes hyperexcitability of the myocardium and causes an increasing 
incidence in the cardiac arrhythmias like ventricular fibrillation leading on to 
sudden cardiac death and also noted that the decreasing hardness of water is 
associated with an acute and chronic coronary artery disease and an increase in 
the sudden death rate. 
(56)
 R. Parsons et al., found that the hardness of water was 
due to the protective factor magnesium. Marier et al., (1968) postulated that the 
higher serum magnesium levels provides protection for the myocardium against 
the ischemic injury and also resists the damage caused by the cardiotoxic 
agents. 
(57)
  
 Magnesium deficiency causes high serum calcium concentration and 
causes spasm of the coronary arteries and also it potentiates the actions of 
norepinephrine, angiotensin, potassium, acetylcholine, and serotonin on the 
coronary arteries and can lead onto increased incidence in coronary artery 
disease and sudden cardiac deaths due to arrhythmias. 
(58) 
 
MAGNESIUM DEFICIENCY IN CRITICALLY PATIENTS  
In critically ill patients many factors contribute to magnesium deficiency 
like nasogastric tube suctioning, impairment in the gastrointestinal absorption, 
poorly low content of magnesium in total parenteral nutrition and intravenous 
administration of drugs like diuretics, aminoglycosides, etc., the table gives us 
the information of various studies conducted on the magnesium levels in the 
critically ill patients. The prevalence of the magnesium deficiency varies from 
15 to 70% in the ICU settings. 
(59)
 They also found that patients with the low 
magnesium levels had severe sepsis, frequently needed mechanical ventilation 
for a longer duration with increase in mortality rates.   
Fig 23: PREVALENCE OF HYPOMAGNESEMIA IN CRITICALLY ILL PATIENTS 
IN VARIOUS STUDIES 
(59) 
 
. 
 
 
 MAGNESIUM DEFICIENCY AND OSTEOPOROSIS: 
           Around 50% of the total magnesium is found in the bones. Therapy with 
magnesium in osteoporotic patients results in osteoblastic activity (bone 
formation).  It does so by keeping the calcium in ionized state and also increases 
the availability of vitamin D. Adequate intake of magnesium is associated with 
increased calcium utilization and retention. Several studies of older adults 
proved that supplementation with magnesium improved the bone mineral 
density (BMD).  
MAGNESIUM DEFICIENCY AND PSYCHIATRIC ILLNESS 
  Depression is considered as a sign of magnesium deficiency as reported 
by National Institute of Health in 2000. Earlier symptoms include anxiety, 
insomnia, poor attention and memory, confusion Obsessive Compulsion 
disorder (OCD). Delirium, depression, hallucinations and dementia 
(Alzheimer’s disease) are associated with very severe magnesium deficiency(60) 
 
EFFECTS OF MAGNESIUM IN OTHER DISEASES 
           Magnesium protects the cell from aluminum, mercury, lead, cadmium, 
beryllium and nickel. Low levels of total body magnesium results in deposition 
of heavy metals in the brain which leads to a predisposition for the development 
of diseases like multiple sclerosis, Parkinson’s and Alzheimer’s disease. In 
children, magnesium deficiency leads in heavy metal toxicity which contributes 
to learning disorders. 
(61)
  
 MAGNESIUM AS A THERAPEUTIC AGENT 
1. For decades, magnesium sulphate has been used safely and successfully to 
prevent eclamptic seizures in the management of pre- eclampsia and eclampsia 
(62). 
 
2. In the management of arrhythmias like digoxin induced arrhythmias and 
torsades de pointes with long QT syndrome. 
3. The role of magnesium in atrial fibrillation needs further studies for evaluation. 
 
 INTRAVENOUS MAGNESIUM SULFATE 
           The ideal neuroprotective agent for stroke would be inexpensive, readily 
available, easy to administer and have no significant adverse side effects. 
Intravenous Magnesium sulphate offers promise as just such an agent. Multiple 
randomized controlled trials had suggested that magnesium has a demonstrable 
neuroprotective potential in acute ischemic strokes, head trauma, spinal cord 
damage and any excitotoxic injury. The readily available source of ionized 
magnesium is the Magnesium sulfate which has an established safety and 
efficacy profile in myocardial infarction, eclampsia and cardiac resuscitation.                           
 
EFFECTS OF MAGNESIUM IN ISCHEMIC STROKE  
ANTAGONISM OF INTRACELLULAR CALCIUM IN THE ISCHEMIC 
CASCADE
(63) 
 Cerebral ischemia by lowering the transmembrane potential opens up the 
calcium channels causing the release of calcium from the sarcoplasmic 
reticulum and the mitochondria. This released calcium hydrolyze the membrane 
phospholipids by the activation of the phospholipases. The damaged membrane 
further increases the influx of calcium producing a positive feedback 
mechanism, by which ischemia produces higher calcium levels. The high levels 
of calcium inside the cell disturb the mitochondrial phosphorylation and 
increase the calcium dependant processes which utilize large amounts of ATP. 
This along with decreased ATP production causes depletion of ATP reserves 
thereby resulting in irreversible cell death. During ischemia, calcium entry into 
the cell is through the N-methyl-D-aspartate (NMDA) subtype of glutamate 
receptor.  
 Many calcium channel blockers were used in the setting of ischemia 
mainly to prevent the vasospasm. They have effect mainly on the calcium 
channels and do not affect the intracellular release of calcium in the damaged 
membranes. Thus magnesium has an advantage in that it has effect on 
antagonizing the intracellular calcium and preventing the positive feedback 
mechanisms.  
 
 
MAGNESIUM: A HIGHLY PROMISING NEUROPROTECTIVE  
 
THERAPY FOR STROKE
 
 
 NEUROPROTECTANT EFFECTS (Fig 24) 
1. VASCULAR EFFECTS  
           Magnesium stimulates the release of prostacyclin from the endothelium. 
Prostacyclin causes vasodilatation and inhibition of the aggregation of the 
platelets. So in deficient states increases the thromboxane/ prostacyclin ratio 
induces platelet aggregation and vasoconstriction. Also magnesium increases 
the endothelial dependant cerebral vasodilatation by stimulating the release of 
NO (nitric oxide) and inhibiting the potent vasoconstrictors mainly calcium and 
PGF2α.
(64)
 This decreases the cerebral vascular resistance thereby increasing the 
cerebral blood flow. It inhibits the aggregation of platelets and prevents the 
propagation of thrombus and re-occlusion of the thrombosed vessels after 
recanalization. 
 Fig 24: POSSIBLE EFFECTS OF MAGNESIUM IN ISCHEMIC STROKE 
2. NEURONAL EFFECTS: ANTIEXCITOTOXIC 
  In the process of ischemic cascade, magnesium prevents the various 
excitatory events leading to ischemic neuronal death which are as follows. 
1. Magnesium is an anti-excitotoxic agent, as it provides a voltage dependent 
block, through which it causes the inhibition of ischemia induced glutamate 
release. 
2. Magnesium binds with ATP and blocks the voltage dependant ion channel of 
the NMDA receptor complex (Fig 25) and in higher doses acts as a non 
competitive N-methyl-D-aspartate (NMDA) receptor antagonist.   
 Fig 25:  NMDA RECEPTOR INHIBITION BY MAGNESIUM 
3. By the inhibition of NMDA receptor, the release of the major excitatory 
neurotransmitter, glutamate is inhibited, which is released excessively from the 
presynaptic neurons by the ischemic damage thereby causing a reduction in the 
post synaptic neurotoxicity. 
4. Magnesium at the presynaptic level prevents the release of excitatory 
neurotransmitters thereby inhibiting the entry of calcium through the voltage 
gated channels. Intracellular magnesium concentrations are sufficiently high to 
antagonise a number of voltage gated ion channels including calcium, sodium 
and potassium, all implicated in cerebral ischemia.
(19)
 
5. After an ischemic event, it enhances the recovery of cellular energy metabolism. 
6. By preventing the cortical spreading depression and by suppression of anoxic 
depolarization, magnesium has the most effective potential neuroprotection.  
7. There is a considerable reduction in the volume of the cerebral infarct. 
8.  The reasons for this improvement are due to the effects of increasing regional 
cerebral blood flow to the ischemic areas, or primarily neuronal actions, or a 
combination of these effects. 
Thus magnesium provides neuroprotection by boosting the tolerance to the 
ischemic insult such that the tissue retains the viability till other defence 
mechanisms come into play. 
           
 
 
  
 
 
 
METHODS AND STUDY DESIGN 
This was a cross sectional study, done in patients admitted in the 
medicine wards in Government Royapettah Hospital, conducted from July 2012 
to December 2012. This study protocol was approved for research studies by the 
Ethical committee Government Kilpauk Medical College Hospital, Chennai. 
INCLUSION CRITERIA                                                                     
30 patients who were admitted in the medicine wards and intensive care 
unit with a diagnosis of acute ischemic stroke were taken as cases. Acute 
ischemic stroke was diagnosed based on the clinical grounds and was later 
confirmed with either the initial CT scan or the delayed CT when the initial CT 
scans were normal. 30 patients were recruited from the outpatient department to 
participate in the study as controls. The age group included in the study was       
> 40 years. Patients with history of diabetes, hypertension and coronary artery 
disease were also included in the study. Written informed consent was obtained 
from the controls and the relatives of the cases and the blood was withdrawn at 
the time of admission to determine the serum magnesium levels. Patients (study 
and control population) were subjected to analysis of serum magnesium using 
colorimetric method. On each patient, complete clinical examination was done 
during the time of admission. Neurological status of the patients suffered from 
stroke was assessed at the time of admission by Glasgow coma scale and during 
discharge using Modified Rankin scale. From all the patients, information on 
medical histories regarding hypertension, diabetes mellitus, coronary heart 
disease, smoking and use of any medications were obtained through 
questionnaire and the patient’s medical records.  
Around 2 ml of venous blood was collected from the patients. Blood was 
allowed to clot and serum was separated by centrifugation and serum 
magnesium was estimated. Similarly blood was collected to check for random 
blood sugar, serum lipid levels. Serum magnesium was estimated by the 
colorimetric method. The normal levels of magnesium are 1.5 – 2.5 mEq/L. 
Patients whose serum magnesium levels were found to be significantly lower 
were treated with intravenous magnesium sulphate.   
EXCLUSION CRITERIA 
1. Chronic kidney disease 
2. Alcoholic liver disease 
3. Thyroid disorders – hypo/hyperthyroidism 
4. Chronic diarrhea 
5. Patients on drugs that affect serum magnesium levels like diuretics, digoxin and 
antibiotics like amphotericin B, amino glycosides.  
 
 
 
STATISTICAL ANALYSIS 
Statistical analysis was done to identify significance and correlation 
between serum magnesium levels and acute ischemic strokes. Statistical 
analysis was done using Statistics Products Services Solutions (SPSS 15) 
software. Univariate analysis was done with paired t test and Pearson product 
moment correlation coefficient. A chi squared test was used to analyze the 
probability of differences in frequency distributions between the groups and 
p<0.05 was taken to be statistically significant in all calculations. 
 VARIABLES MEASURED IN THE STUDY 
           The important variables measured in the study are the serum magnesium 
levels compared with the age, sex, systolic and diastolic blood pressure, random 
blood sugar values, HDL, LDL cholesterol and the neurological outcomes of the 
acute ischemic stroke patients using Glascow coma scale and Modified Rankin 
scale. (Fig 26,27). 
        
Fig 26: GLASCOW COMA SCALE 
 
Fig 27: MODIFIED RANKIN SCALE 
OBSERVATIONS AND RESULTS OF THE STUDY 
COMPARISON OF THE MAGNESIUM DEFICIENCY WITH THE VARIABLES 
VARIABLES: 
1. AGE AND SEX OF THE PATIENT  
                              Among the study population, 30 patients of stroke 
patients, in the age group 45 – 80 years. Maximum incidence of stroke in the 
study was in the age group of 61 -70 years. Maximum incidence of age group in 
the control is 51 – 60 years. The percentage of smokers in both the case and 
control population was approximately 40%. So smoking as a confounding 
variable is removed. In both the cases and the controls, male (60%) to female 
ratio (40%) was 3:2. In the study, it was found that the cases were above the age 
of 45 years and below 80 years with the majority of cases were within the sixth 
decade.   
 
60% 
40% 
CHART 1:  SEX RATIO OF THE CASES AND 
CONTROLS 
 
MALES 
FEMALES 
TABLE 1: PERCENTAGE OF MALES AND FEMALES IN THE 
CASES AND CONTROLS 
 
 
  
SEX 
Total    Male Female 
Group Case Count 18 12 30 
% within 
Group 
60.0% 40.0% 100.0% 
Control Count 18 12 30 
% within 
Group 
60.0% 40.0% 100.0% 
Total Count 36 24 60 
% within 
Group 
60.0% 40.0% 100.0% 
  P=1.000 
3. MAGNESIUM 
In the study, serum magnesium was below the normal range in 70% of the 
cases and 26.6% of the controls. Male distribution: 43.33% and female 
distribution: 26.67%. The maximum incidence of magnesium deficiency for 
both males and females in the stroke population were in the age group of 61 – 
70 years which contributed to around 50% of the study population.  Patients 
who were severely deficient were also in the age group of 61 – 70 years. The   
mean serum magnesium levels were significantly lower in the stroke patients 
(1.46) compared to the controls (1.83). 
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TABLE 2: AGE AND SEX DISTRIBUTION OF STROKE PATIENTS ACCORDING 
TO THE SERUM MAGNESIUM LEVELS 
 
AGE 
 
SEX 
 
SERUM 
MAGNESIUM 
< 1.0 mg/dl 
 
 
SERUM 
MAGNESIUM 
1.0 – 1.5 mg/dl 
 
 
SERUM 
MAGNESIUM 
>1.5  mg/dl 
 
40 – 50 
YEARS 
MALE 0 2 3 
FEMALE 1 0 0 
 
51 – 60YRS 
MALE 0 4 2 
FEMALE 0 0 3 
 
61 – 70 YRS 
 
MALE 3 2 0 
FEMALES 1 3 1 
 
71 – 80 
YEARS 
MALES 1 1 0 
FEMALES 0 0 3 
TOTAL MALES 4 9 5 
FEMALES 5 3 4 
 
RESULT 
 
MAGNESIUM DEFICIENT -  70% 
MALES: 43.33% 
FEMALES : 26.67% 
 
 
SUFFICIENT – 30% 
 
TABLE 3: PREVALENCE OF SERUM MAGNESIUM DEFICIENCY IN 
CASES AND CONTROLS 
   
Serum magnesium 
Total 
   Severe 
<1.0 
Mild 
1 – 1.5 
Normal 
>1.5 
Group Case Count 8 13 9 30 
% within Group 26.7% 43.3% 30.0% 100.0% 
Control Count 4 4 22 30 
% within Group 13.3% 13.3% 73.3% 100.0% 
Total Count 12 17 31 60 
% within Group 20.0% 28.3% 51.7% 100.0% 
P=0.003 
 
4. SYSTEMIC HYPERTENSION 
Hypertension was present in 60% of the cases and 40% of the controls. In 
the stroke patients and the controls, the mean systolic and diastolic blood 
pressure was significantly higher in the patients with magnesium deficiency 
compared to the patients with the normal magnesium levels.  
  
TABLE 4: PERCENTAGE OF HYPERTENSION IN THE 
CASES AND CONTROLS 
   SHT 
Total    Yes No 
Group Case Count 18 12 30 
% within Group 60.0% 40.0% 100.0% 
Control Count 12 18 30 
% within Group 40.0% 60.0% 100.0% 
Total Count 30 30 60 
% within Group 50.0% 50.0% 100.0% 
P=0.196 
 
< 180 181 - 220 > 220 
1 
5 5 
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CHART 5: COMPARISON OF SERUM MAGNESIUM LEVELS 
WITH SYSTOLIC BLOOD PRESSURE    
 < 1 1 - 1.5 > 1.5 
     
In the cases, from this table we see that, lower the serum magnesium 
levels, higher the systolic and the diastolic blood pressure during presentation.  
T-Test 
TABLE 5: MEAN VALUE OF SERUM MAGNESIUM IN PATIENTS 
WITH AND WITHOUT HYPERTENSION IN THE TOTAL 
POPULATION 
 SHT N Mean Std. Deviation P-value 
SERUM 
MAGNESIUM 
Yes 30 1.4133 .55319 
0.031 
No 30 1.7400 .58933 
< 110 110 - 140 > 140 
0 
3 4 2 
10 
2 
3 
5 
1 
CHART 6: COMPARISON OF SERUM MAGNESIUM LEVELS 
WITH DIASTOLIC BLOOD PRESSURE    
 
< 1 1 - 1.5 > 1.5 
 5. DIABETES MELLITUS 
TABLE 6: PERCENTAGE OF DIABETES MELLITUS IN THE 
CASES AND CONTROLS 
   DM 
Total    Yes No 
Group Case Count 17 13 30 
% within Group 56.7% 43.3% 100.0% 
Control Count 12 18 30 
% within Group 40.0% 60.0% 100.0% 
Total Count 29 31 60 
% within Group 48.3% 51.7% 100.0% 
P=0.301 
          Diabetes mellitus was present in 57% of the cases and 40% of the 
controls. The mean random blood sugar values in the cases were higher when 
compared to the controls. The random blood sugar values were comparatively 
higher at the time of admission in the magnesium deficient compared to the 
patients with the normal levels in patients with the stroke. 
 
T-Test 
TABLE 7: MEAN VALUE OF SERUM MAGNESIUM IN PATIENTS 
WITH AND WITHOUT DIABETES IN THE TOTAL POPULATION 
 DM N Mean Std. Deviation P-value 
SERUM 
MAGNESIUM 
Yes 29 1.3759 .66475 
0.011 
No 31 1.7645 .44388 
 
6. CORONARY HEART DISEASE 
TABLE 8: PERCENTAGE OF CORONARY HEART DISEASE 
IN THE CASES AND CONTROLS 
   CAD 
Total    Yes No 
Group Case Count 14 16 30 
% within Group 46.7% 53.3% 100.0% 
Control Count 12 18 30 
% within Group 40.0% 60.0% 100.0% 
Total Count 26 34 60 
% within Group 43.3% 56.7% 100.0% 
P=0.795 
   The coronary heart disease was present in 47% of the cases 
and 40% of the controls. In both the case and the control population, patients 
with systemic hypertension, diabetes mellitus and coronary heart disease 
considerably found to have significantly lower levels of serum magnesium than 
those who don’t have. 
T-Test 
TABLE 9: MEAN VALUE OF SERUM MAGNESIUM IN PATIENTS 
WITH AND WITHOUT CORONARY HEART DISEASE IN THE 
TOTAL POPULATION 
 CAD N Mean Std. Deviation P-value 
SERUM 
MAGNESIUM 
Yes 26 1.3923 .61834 
0.033 
No 34 1.7176 .53455 
 
 
SHT DM CAD 
71% 62% 52% 
44% 44% 33% 
CHART 7:  PERCENTILE OF HYPERTENSION (SHT), 
DIABETES(DM), CORONARY ARTERY DISEASE(CAD) 
COMPARED WITH SERUM MAGNESIUM LEVELS 
< 1.5 > 1.5 
 From this chart, we infer that percentage of stroke patients with the risk 
factors namely systemic hypertension, diabetes and coronary artery disease are 
deficient in serum magnesium which evidences that the development of the 
these risk factors can be secondarily due to magnesium deficiency. 
 
7. HDL CHOLESTEROL 
TABLE 10: PERCENTAGE OF HDL CHOLESTROL IN THE CASES 
AND CONTROLS 
 
 
   HDL_GP 
Total    <40 >=40 
Group Case Count 18 12 30 
% within Group 60.0% 40.0% 100.0% 
Control Count 10 20 30 
% within Group 33.3% 66.7% 100.0% 
Total Count 28 32 60 
% within Group 46.7% 53.3% 100.0% 
P=0.070 
CHART 8: CORRELATION OF HDL LEVELS WITH THE SERUM MAGNESIUM 
LEVELS 
 
8. LDL CHOLESTEROL 
TABLE 11:PERCENTAGE OF LDL CHOLESTROL IN THE CASES AND 
CONTROLS 
   LDL_GP 
Total    <=130 131-160 >160 
Group Case Count 2 10 18 30 
% within Group 6.7% 33.3% 60.0% 100.0% 
Control Count 16 6 8 30 
% within Group 53.3% 20.0% 26.7% 100.0% 
Total Count 18 16 26 60 
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TABLE 11:PERCENTAGE OF LDL CHOLESTROL IN THE CASES AND 
CONTROLS 
   LDL_GP 
Total    <=130 131-160 >160 
Group Case Count 2 10 18 30 
% within Group 6.7% 33.3% 60.0% 100.0% 
Control Count 16 6 8 30 
% within Group 53.3% 20.0% 26.7% 100.0% 
Total Count 18 16 26 60 
% within Group 30.0% 26.7% 43.3% 100.0% 
P=0.000 
CHART 9: CORRELATION OF LDL LEVELS WITH THE SERUM MAGNESIUM 
LEVELS 
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  From these tables it can be found that that levels of HDL cholesterol were 
lower < 40 mg/dl and LDL cholesterol were comparatively higher > 130 mg/dl 
in magnesium deficient patients for both the cases and the controls.  In the 
stroke patients compared to the controls, HDL cholesterol was lower and LDL 
cholesterol was higher. 
  From this graph chart, it can be identified that from the study, the mean 
values of systolic and diastolic blood pressure and LDL cholesterol were 
significantly higher in the magnesium deficient and HDL cholesterol was lower 
compared to the cases with the normal magnesium levels. 
 
TABLE 12: COMPARISON OF MEAN VALUES OF THE VARIABLES IN THE 
CASE AND CONTROL POPULATION 
Group AGE SBP DBP GCS HDL LDL 
Serum 
magnesium 
Blood 
sugar 
Case Mean 60.17 194.13 120.40 10.43 38.57 177.50 1.390000 164.73 
N 30 30 30 30 30 30 30 30 
Std. Deviation 9.377 34.224 16.786 3.411 10.647 37.175 .5944282 63.725 
Control Mean 61.17 129.80 85.00  42.47 138.67 1.763333 143.53 
N 30 30 30  30 30 30 30 
Std. Deviation 9.370 26.368 16.348  8.241 33.365 .5320639 53.402 
Total Mean 60.67 161.97 102.70 10.43 40.52 158.08 1.576667 154.13 
N 60 60 60 30 60 60 60 60 
Std. Deviation 9.308 44.381 24.258 3.411 9.642 40.123 .5901355 59.262 
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CHART 10: COMPARISON OF MEAN VALUES OF THE 
VARIABLES WITH THE SERUM MAGNESIUM LEVELS  
CASES 
CONTROLS 
  
 
TABLE 13: p VALUE OF THE DIFFERENT VARIABLES 
 Group N Mean Std. Deviation P-value 
AGE Case 30 60.17 9.377 
0.681 
Control 30 61.17 9.370 
SBP Case 30 194.13 34.224 
0.000 
Control 30 129.80 26.368 
DBP Case 30 120.40 16.786 
0.000 
Control 30 85.00 16.348 
MAGNESIUM SBP DBP HDL LDL RBS 
1.04 
204 
126 
34.8 
187 
173 
2.18 
170 
107 
47.33 
154 
144 
CHART 11: COMPARISON OF MEAN VALUES OF THE 
VARIABLES WITH THE SERUM MAGNESIUM LEVELS 
IN THE STROKE PATIENTS 
 
<1.5 >1.5 
HDL Case 30 38.57 10.647 
0.118 
Control 30 42.47 8.241 
LDL Case 30 177.50 37.175 
0.000 
Control 30 138.67 33.365 
Serum 
magnesium 
Case 30 1.390000E0 .5944282 
0.013 
Control 30 1.763333E0 .5320639 
Blood sugar Case 30 164.73 63.725 
0.168 
Control 30 143.53 53.402 
 
From this table, we can find that p value was significant (<0.05) for 
serum magnesium (p = 0.013), systolic and diastolic blood pressure (p = 0.00), 
LDL cholesterol (p = 0.00) which proves the association of these variables with 
the serum magnesium.  
 
 
 
 
 
 
9. NEUROLOGICAL OUTCOME OF THE STROKE PATIENTS 
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In the study population of stroke patients, the neurological outcome was 
assessed. The Glascow coma scale was lower at the time of admission and the 
Modified Rankin scale was higher during discharge in the patients with the low 
serum magnesium levels compared to the patients with normal levels. This 
showed that the severely magnesium deficient patients have a poor neurological 
outcome in patients suffered from stroke.  
 
 
 
 
 
LIMITATIONS OF THE STUDY 
 
1. The study was conducted in a sample size of only 30. Further studies need to be 
carried in a larger study population to verify the results and to show that there is 
a significant relationship between the serum magnesium and ischemic stroke.  
2. The study was conducted only in the patients with acute ischemic 
cerebrovascular accidents. The haemorrhagic strokes and transient ischemic 
attacks were not considered in the study. So further studies trials have to be 
conducted on all the three types of strokes to verify the relationship between 
these.  
 
 
 
 
 
 
 
 
 
DISCUSSION 
 The prevalence of serum magnesium deficiency in acute ischemic 
cerebrovascular accidents was studied and found that there was a significant 
correlation between serum magnesium levels and the stroke. The mean serum 
magnesium levels were significantly lower in the cases (1.39) than the controls 
(1.76) (p=0.00) among the 30 patients with stroke, 70% (21) of them had 
magnesium levels below 1.5 and only 30% (9) of them had normal magnesium 
levels. The maximum incidence of deficiency in the cases occurred in the sixth 
decade. Overall, most of them who had lower magnesium levels also had 
multiple risk factors for stroke in both the cases and the controls.  Thus 
magnesium deficiency is also associated with these risk factors for 
cardiovascular diseases like systemic hypertension, (p=0.00) diabetes, coronary 
artery disease and dyslipidemia (p=0.00).  
According to a case – control pilot study conducted by the University 
College of Medical Sciences (UCMS), New Delhi in the north Indian 
population, and serum magnesium was measured in 50 diagnosed cases of acute 
stroke which included transient ischemic attacks, ischemic and hemorrhagic 
strokes. It was a similar type of our study and the results were that the patients 
who had suffered ischemic stroke had significantly lower magnesium levels 
than the controls and also in patients who had suffered hemorrhagic strokes and 
transient ischemic attacks. Our study did not include strokes other than ischemic 
and the study population included only thirty cases and controls, but the 
observation was similar to theirs and was statistically significant. Their study 
did not include the diabetic population. Our study found that significant 
population of magnesium deficient patients were also diabetics, had 
dyslipidemia and hypertension. Hence in our study, hypertension and diabetes 
mellitus were found to be the important mediating factors associating serum 
magnesium with the ischemic stroke. 
  
Many epidemiological studies reported that there was inverse relationship 
between the cardiovascular risk factors like hypertension, diabetes and the 
metabolic syndrome. In the Atherosclerosis Risk in Communities (ARIC) 
Study, they studied the relationship of the serum magnesium levels and the 
dietary intake in 14,221 males and females aged 45 – 64 years. They were 
followed up for fifteen years and 577 strokes occurred. It was observed that the 
incidence of stroke was higher in patients with low magnesium level and also 
the prevalence of hypertension and diabetes is lower in the population with the 
higher magnesium levels. They reported that the increased risk is mainly 
through the primary effects of magnesium on diabetes and hypertension. But in 
contrary, they also noted that dietary magnesium intake had only a marginal 
inverse association with the ischemic strokes. 
 
There are ample amount of mounting evidence to prove that magnesium 
play a critical role in causing stroke and also in the healing process that take 
place during and also after the event of stroke.  
 
After conducting various clinical trials, the American Journal of Clinical 
Nutrition and Reuters published that for every extra 100 milligrams of 
magnesium intake per day decreased the risk of an ischemic stroke by 9%.  
  
A meaningful study was conducted in New York in the emergency 
department of three hospitals in 100 patients who had suffered from stroke. It 
established that in a significant number of patients there was a demonstrable 
deficiency of magnesium. It also exhibited these patients also had high calcium 
to magnesium ratio which are signs of increased vascular tone and vasospasm.  
 
Magnesium in drinking water exists in a hydrated form and thus is easily 
more absorbed. In Taiwan, it was identified that the increase in hardness of 
water which is determined by the mineral content of calcium and magnesium 
was associated with a decrease in morbidity and mortality from cardiovascular 
and cerebrovascular diseases. A study compared all deaths due to stroke among 
their residents (17,133 cases) of Taiwan compared with all deaths from other 
causes (17,133 controls) conducted from 1989 till 1993. It was found that in the 
drinking water consumed by the Taiwan residents, higher the magnesium levels, 
the lower the incidence of stroke. This showed that magnesium had a significant 
protective effect from the drinking water on the risk of cerebrovascular diseases.  
  
In the Journal of the American Academy of Nurse Practitioners published 
in 2009 by the Brigham Young University that from population based studies, 
the clinical evidence suggests that people are in greater risk for stroke who 
consumed low magnesium in their diet.   
            
Every moment in stroke is crucial to outcome. In any untreated stroke, 
ischemic cascade injury process kills 12 million brain cells in a minute. 
Experimental studies had proved that magnesium slows this injurious process. 
Eight of the nine preclinical trials had demonstrated a significant decrease in 
sizes of the infarct volume treated with magnesium sulphate in animal acute 
ischemic stroke models. So magnesium has the ability to limit the area of infarct 
that is permanently lost as a result of stroke. 
   
          The IMAGES (Intravenous Magnesium Efficacy in Stroke) trial is an 
international RCT that was conducted on 2,386 patients treated with IV 
magnesium sulfate started within 12 hours after the onset of stroke (16 
millimoles over 15 minutes, then 65 millimoles over 24 hours). The 90-day 
survival and disability data was followed on these patients. It showed a positive 
trend in protecting the patients with noncortical stroke. 
 Field Administration of Stroke Therapy- Magnesium (FAST-MAG) trial 
 is a large trial sponsored by NIH-NINDS, conducted in Los Angeles, California 
to find the effects of intravenous magnesium for very early stroke. This trial 
found that there was a dramatic early recovery in 42 percent of patients infused 
with magnesium within two hours onset of stroke onset. In about 69% of all the 
patients and in 75% of patients infused with magnesium within two hours of 
stroke onset, good global function was achieved at 90 days after the onset of 
stroke. This trial was conducted primarily in the field, where magnesium 
sulphate can be easily given, efficacious and can be given over a wide range of 
dose.  
 
This unique trial hopes to demonstrate “pre-hospital initiation” whether 
magnesium infusion therapy, mostly via paramedics, can be effective in halting 
or slowing the ischemic cascade in most patients within those first crucial two 
hours. If this bold field trial proves to improve stroke outcome, it could usher in 
a new era of acute stroke management since rtPA cannot realistically be 
administered in the field. 
Stroke remains the leading cause of disability worldwide. Unfortunately, 
the current therapies used in acute ischemic strokes are of extremely limited 
utility. The ideal neuroprotective agent for stroke should be inexpensive, readily 
available, easy to administer, have no significant adverse side effects with the 
added advantage of earlier administration even prior to obtaining a CT or a MRI 
brain scan. Magnesium offers promise as such an agent. The present study 
provided some evidence that serum magnesium can be considered as a 
modifiable risk factor in the development of acute ischemic stroke primarily by 
preventing the endothelial dysfunction which is the initiating event in the 
development of atherosclerotic plaque. So, if therapeutically intervened early in 
the course of the disease using magnesium as an adjuvant therapy for patients 
with the risk factors for stroke, it can prevent or modify the subsequent risk of 
developing cardiovascular events. Further studies, with larger populations, are 
needed to prove our findings. 
 
 
 
 
 
 
 
IMPLICATIONS FOR THE FUTURE 
 
1. Serum magnesium levels should be done as a screening for patients who have 
the risk factors for stroke like diabetes mellitus, hypertension, dyslipidemia and 
coronary artery disease.  
2. If they are found to be deficient, even if they are asymptomatic, they can be 
benefitted by advising the patient to increase the daily intake of magnesium in 
food or by supplementing with drugs. 
3. Most of the available experimental trials and studies on magnesium have been 
conducted in countries outside India. 
4.  In India, there is not much study done on serum magnesium. To highlight its 
association with systemic hypertension, diabetes, coronary artery disease and 
cerebrovascular accidents, further trials with a larger population need to be 
carried out in our country to document the prevalence of serum magnesium 
deficiency and its association with cardiovascular risk factors.   
       
CONCLUSION 
In conclusion, the present study showed a statistically significant 
correlation between the serum magnesium deficiency with the ischemic stroke. 
It is also associated with its risk factors diabetes, systemic hypertension and 
dyslipidemia which are important factors mediating association of serum 
magnesium with the incidence of ischemic stroke. Higher serum magnesium 
levels are accompanied by higher function and better prognosis after a stroke. 
So if a patient with the risk factors for stroke is found to have low levels of 
magnesium during screening, prophylactic supplementation with magnesium 
can prevent the more disability in the persons that will be involved by stroke in 
future and can reduce the social, emotional and economical losses among them. 
 
Disclosure 
          The investigator had not received any form of support or grant from any 
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ABBREVIATIONS  
 
rt- PA – recombinant tissue plasminogen activator 
WHO - World Health Organization 
ICMR - Indian Council of Medical Research 
DALYS - Disability adjusted life years 
NCD - Non communicable diseases 
DTN - door to needle 
EAA - Excitatory Amino Acid 
NMDA – N- methyl D- aspartate 
PET – Positron Emission Tomography 
ATP - adenosine tri phosphate 
NO – Nitric oxide 
RBC – Red blood cell 
Mg
2+
 - magnesium  
Ca 
2+ 
- calcium 
mEq/L – milli equivalents per litre 
NIH - National Institute of Health 
RDA – Recommended daily allowance 
FE - Fractional excretion 
CRP - C- reactive protein 
ARIC – Atherosclerosis Risk in Communities 
VCAM - vascular cell adhesion molecule 
MCP-1 - monocyte chemoattractant protein -1 
PDGF - platelet derived growth factor 
NFkβ - nuclear factor kappa- light chain- enhancer of activated B cells 
IF – interferons 
IL – interleukins 
LDL – Low density lipoprotein 
HDL – High density lipoprotein 
HMG-CoA – 3-hydroxy-3-methyl-glutaryl-CoA reductase 
TGL - Triglyceride 
DASH - Dietary Approaches to Stop Hypertension 
BMD - bone mineral density 
CT – Computed tomography 
GCS – Glascow coma score 
MRS – Modified Rankin scale 
  
 
 
 
 
 
 
 
QUESTIONNAIRE 
 
Name / Age / Sex / Occupation / Address/IP/OP Number. 
 
HISTORY 
Unilateral weakness of limbs, loss of consciousness, seizures, giddiness, 
syncope, headache, vomiting - duration, onset, progression 
PAST HISTORY  
Diabetes Mellitus, Systemic Hypertension, Dyslipidemia, Cardiovascular 
Disease, Cerebrovascular Disease, Peripheral Vascular Disease, Thyroid 
Disorders, Liver Diseases, Renal Failure, Chronic diarrhoea 
PERSONAL HISTORY  
Alcohol - amount, frequency, duration 
Smoking - beedi/cigarette, number/day, duration 
DRUG HISTORY  
• Magnesium  supplementation 
• Anti Diabetic , Anti Hypertensive Medications , Cardiac Drugs 
(Diuretics) 
• Drugs affecting Serum Magnesium Levels 
ON EXAMINATION 
 General Examination  
 Vital Signs - Pulse Rate, Blood Pressure, Respiratory Rate 
 Systemic Examination -  CVS , RS , Abdomen , CNS 
       
INVESTIGATIONS 
• Serum magnesium 
• Blood Sugar – FBS, PPBS 
• Lipid Profile 
• Renal Function Tests 
• Liver Function Tests 
• Thyroid Function Tests 
• ECG  
• CXR             
• CT Brain 
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